View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, April 12 (HealthDay News) -- At two years of follow-up, diabetes-related clinically significant macular edema (CSME) is more effectively improved by intravitreous bevacizumab than with macular laser therapy (MLT), according to a study published online April 9 in the Archives of Ophthalmology.
Ranjan Rajendram, M.D., of Moorfields Eye Hospital in London, and colleagues randomized 80 patients with center-involving CSME and visual acuity of 20/40 to 20/320 to receive either bevacizumab or MLT. The outcomes were reported at two years.
At two years, the researchers found that the mean Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity was significantly better in the bevacizumab arm than the MLT arm (64.4 versus 54.8; P = 0.005). The bevacizumab arm gained significantly more ETDRS letters than the MLT arm (median of nine versus 2.5; mean gain of 8.6 versus mean loss of 0.5). At least 10 letters were gained by 49 percent and at least 15 by 32 percent in the bevacizumab arm, compared with 7 and 4 percent, respectively, in the MLT arm. Central macular thickness was reduced by a mean 146 µm in the bevacizumab arm, compared with 118 µm in the MLT arm. The bevacizumab group received a median of 13 treatments over the 24 months, while the MLT group received four.
"This study provides evidence supporting longer-term use of intravitreous bevacizumab for persistent center-involving CSME," the authors write.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top